Compare KTCC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTCC | RNXT |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 37.0M |
| IPO Year | 1995 | 2021 |
| Metric | KTCC | RNXT |
|---|---|---|
| Price | $3.76 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 27.9K | ★ 285.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,871,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.40 | $0.70 |
| 52 Week High | $4.20 | $1.45 |
| Indicator | KTCC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 54.28 |
| Support Level | $2.57 | $0.80 |
| Resistance Level | $4.20 | $1.07 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 44.30 | 53.11 |
Key Tronic Corporation provides electronic manufacturing services, including engineering, materials management, manufacturing and assembly, in-house testing, and distribution to various countries. The company serves diverse industries such as pest control, personal protection, air purification, automotive, medical technology, and utilities inspection equipment. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly. Key Tronic operates manufacturing facilities in the United States, Vietnam, and Mexico, recently expanding with a new facility in Arkansas. Revenue is generated mainly through contract manufacturing and service agreement.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.